Business Context and Reporting Period
This Form 6-K filing by Brainsway Ltd., a foreign private issuer, covers the month of July 2019. The report, dated July 18, 2019, serves to disclose a specific corporate event rather than providing periodic financial results.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is an event-based report and does not contain financial statements or performance metrics.
Material Changes
The primary material event disclosed is the announcement of a groundbreaking study demonstrating the advantages of BrainsWay Deep TMS in treating Major Depressive Disorder. This information is incorporated by reference via Exhibit 99.1.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future outlook, or a discussion of risks and contingencies beyond the context of the clinical study announcement.
Key Facts for Investor Verification
- Verify the full details and methodology of the "Groundbreaking Study" referenced in Exhibit 99.1.
- Confirm the clinical significance and regulatory implications of the Deep TMS results for Major Depressive Disorder.
- Note that no financial performance data is included in this specific filing.